FMI Reports Strong 11.7% CAGR Growth Outlook for the GLP-1 Receptor Agonist Market Through 2035
Comunicato Precedente
Comunicato Successivo
Manufacturers Accelerate Innovation as Demand for Metabolic Therapies Intensifies
Pharmaceutical manufacturers are rapidly advancing self-administration devices, parenteral innovations, and combination therapies to elevate patient adherence and treatment outcomes. The industry is experiencing:
"GLP-1 receptor agonists have evolved from single-indication diabetes drugs to multi-benefit metabolic therapies," said an FMI spokesperson. "Manufacturers investing in delivery innovation, stability optimization, and oral alternatives are expected to lead the next decade of growth."
Exenatide Remains the Market Leader in 2025
Exenatide continues to command 24.4% of the drug-class share, supported by its strong safety record, clinical familiarity, and availability in both short-acting and extended-release forms. Increasing generic penetration is unlocking new affordability and accessibility, enabling wider adoption in emerging markets.
Parenteral Formulations Dominate with 63.2% Share
Parenteral delivery remains the gold standard due to optimal bioavailability for peptide-based therapies. Manufacturers' ongoing advancements in long-acting injectables and user-friendly pen devices are expected to maintain the segment's leading position over the decade.
Diabetes: The Core Indication with 59% Market Share
With nearly 90% of global diabetes cases attributed to type 2 diabetes, the demand for GLP-1 receptor agonists continues to grow rapidly. Their proven efficacy in:
positions them as a cornerstone in modern diabetes treatment guidelines. Improved insurance coverage and early-diagnosis initiatives are driving prescription volumes across major markets
Regional Growth Outlook: India and China Lead the Global Acceleration
FMI's country-wise analysis shows exceptional growth potential:
China
With urbanization, lifestyle shifts, and healthcare reforms, China's diabetic population is among the world's largest. Accessibility to advanced GLP-1 therapies continues improving under government-led healthcare expansion.
India
India represents the world's fastest-growing metabolic medicine market. High genetic predisposition, rising obesity rates, and improved awareness of early diabetes management are generating extraordinary demand for GLP-1 therapies.
United Kingdom
With a mature healthcare ecosystem, the UK continues to expand access through NHS coverage and proactive preventive-care programs.
Competitive Landscape: Manufacturers Strengthen Pipelines Amid Global Demand
Leading companies are focusing on clinical trials exploring cardiovascular outcomes, beta-cell preservation, and novel GLP-1/GLP-2 combinations. Major players include:
Request Full Report Sample pages - https://www.futuremarketinsights.com/reports/sample/rep-gb-12346
Recent Innovations and Market-Shaping Developments
Market Challenges
Despite strong momentum, FMI highlights several barriers:
About the Report
FMI's GLP-1 Receptor Agonist Market Report covers:
The complete report is available for access upon purchase FMI Lucrative Dashboard -
https://www.futuremarketinsights.com/checkout/12346
For Yearly Subscription Please Contact us here - sales@futuremarketinsights.com
New Report on GLP – 1 along with Healthcare Trending Report-
Why FMI - https://www.futuremarketinsights.com/why-fmi
FMI iDEA Methodology - https://www.futuremarketinsights.com/methodology
About FMI (Future Market Insights, Inc.):
Future Market Insights (FMI) is a leading provider of market intelligence, offering in-depth research across pharmaceuticals, healthcare, biotechnology, and life sciences. With a global research network and advanced analytical frameworks, FMI supports manufacturers, investors, policymakers, and stakeholders in making informed strategic decisions.
Media Contact
Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 702-892-0828
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fmi-reports-strong-11-7-cagr-growth-outlook-for-the-glp-1-receptor-agonist-market-through-2035--302631818.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
